Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

PURPOSE: This study aimed to determine activity and safety of weekly bortezomib and rituximab in patients with relapsed/refractory Waldenström macroglobulinemia (WM). PATIENTS AND METHODS: Patients who had at least one previous therapy were eligible. All patients received bortezomib intravenously we...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ghobrial, Irene M., Hong, Fangxin, Padmanabhan, Swaminathan, Badros, Ashraf, Rourke, Meghan, Leduc, Renee, Chuma, Stacey, Kunsman, Janet, Warren, Diane, Harris, Brianna, Sam, Amy, Anderson, Kenneth C., Richardson, Paul G., Treon, Steven P., Weller, Edie, Matous, Jeffrey
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2010
Soggetti:
Original Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2834499/
https://ncbi.nlm.nih.gov/pubmed/20142586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.3237
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi